CELESTONE SOLUSPAN (betamethasone acetate) · Merck
CELESTONE SOLUSPAN is an injectable suspension containing a combination of betamethasone sodium phosphate and betamethasone acetate. It is indicated for the treatment of severe, chronic, or incapacitating conditions when oral therapy is not feasible. Its broad indications include the control of intractable allergic states (e.g., asthma, drug hypersensitivity), dermatologic diseases (e.g., pemphigus, severe erythema multiforme), and endocrine disorders such as congenital adrenal hyperplasia. It is also used for the palliative management of neoplastic diseases (leukemias/lymphomas), acute exacerbations of multiple sclerosis, and to tide patients over critical periods of gastrointestinal diseases like ulcerative colitis and regional enteritis.
How CELESTONE SOLUSPAN Works
Betamethasone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive activity. It diffuses across cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) on DNA, altering gene expression. This results in the induction of anti-inflammatory proteins (such as lipocortins, which inhibit phospholipase A2) and the inhibition of the synthesis of pro-inflammatory mediators (including prostaglandins, leukotrienes, and various cytokines). The SOLUSPAN formulation provides a dual-effect profile: the highly soluble betamethasone sodium phosphate provides rapid activity, while the slightly soluble betamethasone acetate provides sustained activity through slower absorption.
Details
- Status
- Prescription
- First Approved
- 1965-03-03
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
Companies
CELESTONE SOLUSPAN Approval History
What CELESTONE SOLUSPAN Treats
21 indicationsCELESTONE SOLUSPAN is approved for 21 conditions since its original approval in 1965. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Asthma
- Atopic Dermatitis
- Contact Dermatitis
- Drug Hypersensitivity
- Allergic Rhinitis
- Serum Sickness
- Transfusion Reaction
- Dermatitis Herpetiformis
- Mycosis Fungoides
- Pemphigus
- Stevens-Johnson Syndrome
- Congenital Adrenal Hyperplasia
- Thyroiditis
- Ulcerative Colitis
- Hemolytic Anemia
- Diamond-Blackfan Anemia
- Pure Red Cell Aplasia
- Thrombocytopenia
- Trichinosis
- Tuberculous Meningitis
- Leukemia
CELESTONE SOLUSPAN Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in CELESTONE SOLUSPAN's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications CELESTONE SOLUSPAN treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to CELESTONE SOLUSPAN
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Merck's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CELESTONE SOLUSPAN FDA Label Details
Indications & Usage
FDA Label (PDF)When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine D...
Explore on TheraRadar
Ulcerative Colitis Drug Landscape 2026
Approved therapies, pipeline drugs, and clinical trial intelligence
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.